Adam S. Kibel, MD, argues that aggressive curative therapy is the best practice for the management of high-risk prostate cancer. He observes that local therapies like surgery, along with combination therapies like external beam radiation therapy plus brachytherapy and androgen deprivation therapy, have shown themselves to be effective for improving overall survival.
Read More
Adam S. Kibel, MD, argues that the preponderance of evidence shows surgery outperforming radiation therapy when treating prostate cancer patients. He discusses the randomized data still needed to accurately compare these two treatments and multiple case series and a meta-analysis that favor surgery in terms of overall survival, as well as the benefit of surgery in terms of providing an opportunity for optimal staging and subsequent treatment.
Read More
Adam S. Kibel, MD, argues that, while it is common to debate the best intervention method for local prostate cancer, there also must be an emphasis on the systemic treatment of micro-metastatic disease in the interest of decreasing disease-specific death. He then reviews the impact of timing, duration, and intensity of systemic therapy on patient outcomes, focusing on four trials evaluating neoadjuvant therapy for high-risk prostate cancer.
Read More